|Bid||1.91 x 0|
|Ask||1.92 x 0|
|Day's Range||1.89 - 1.94|
|52 Week Range||0.55 - 2.79|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||0.43 (36.61%)|
|1y Target Est||3.05|
FRA: 8IS1) is pleased to announce that today, Gene Simmons, Chief Evangelist Officer for the company and its management team opened the trading day at the TSX Venture Exchange (TSXV). The appearance coincides with the company changing its share ticker from IMH to GENE.
FRA: 8IS1) is pleased to announce that the Company is changing its ticker on the TSX Venture Exchange from IMH to GENE effective on March 20, 2018. "The change in our share ticker to GENE reflects the participation of music legend and media mogul Gene Simmons, who joins Invictus as Chief Evangelist Officer and our enterprise vision of providing multiple genetics/strains to cannabis consumers globally as regulations permit" said Invictus Chairman and CEO Dan Kriznic.
The partnership involves Simmons' leadership in a variety of capacities focused on assisting the Company with its public awareness strategy and eventual branding strategy for the recreational market that is anticipated to be legal in Canada in 2018. His responsibilities will include providing marketing counsel, serving as a spokesperson in the media, public appearances and participation in the Company's annual general meeting and investor meetings, among others. "Gene Simmons is a branding and merchandising genius, who not only created one of the most iconic bands of all time, but has spent decades building successful brands internationally in various industries," said Dan Kriznic, Chairman and CEO of Invictus.
FRA: 8IS1) Acreage Pharms Ltd. ("Acreage Pharms") is pleased to announce that it has received notification from Health Canada (HC) that its sales license inspection has been scheduled for later in March and is anticipated to take up to three days. The Sales License Inspection is the last step prior to the issuance of a Sales License under the Access to Cannabis for Medical Purposes Regulations (the "ACMPR"). "As there are currently only 40 cannabis sales licenses under the ACMPR in Canada, receiving confirmation of our Sales License Inspection from Health Canada is a major milestone for Acreage Pharms.
FRA: 8IS1) AB Laboratories Inc. ("AB Labs") is pleased to announce the closing of the acquisition of the land and building (the "Property") next door for $5.2 million for its Phase 2 expansion. The address of the Property has been consolidated with AB Labs existing address to allow the existing cultivation and sales license to extend to the Property. The milestone allows AB Labs to continue moving ahead with its aggressive cannabis production capacity, as Canada marches towards full legalization during 2018. "Acquiring and consolidating these facilities at AB Labs has been of keen importance and we are delighted to formally secure the merging of the facilities and to begin the next steps towards delivering AB Labs to full production," said Dan Kriznic, Chairman and CEO of Invictus.
NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
FRA: 8IS1) Acreage Pharms Ltd. ("Acreage Pharms") is pleased to announce it has acquired 23 new cannabis strains. This marks an important step in Acreage Pharms' march towards full-capacity cannabis production and sale this year. "The acquisition of these strains broadens Acreage Pharms strain variety in preparation for the recreational market," said Dan Kriznic, Chairman and CEO of Invictus.
FRA: 8IS1) Acreage Pharms Ltd. ("Acreage Pharms") is pleased to announce construction of its Phase 2 facility is nearly complete, putting Acreage Pharms on track for 5,000 kg of cannabis production capacity this month. "Facility construction is one of the foundations of our progress at this point, and we are thrilled that our teams of building specialists are completing work on this ambitious schedule on time," said Dan Kriznic, Chairman and CEO of Invictus. Both the Phase 1 and Phase 2 facilities at Acreage Pharms, located in west-central Alberta, have a total of approximately 40,000 square feet with expected 5,000 kg of capacity beginning in February 2018, along with a further planned 80,000 square foot Phase 3 expansion for total combined production capacity of 19,000 kg in 2018.
FRA: 8IS1) is pleased to announce that the Company has completed the previously announced further strategic investment in the licensed production facility under the Access to Cannabis for Medical Purposes Regulations ("ACMPR"), AB Laboratories Inc. ("AB Labs") located near Hamilton, Ontario, from its current 33.3% ownership interest to 50%. Dan Kriznic, Chairman and CEO commented, "This is another significant milestone for Invictus. When we started this company in 2014 it was with the intention of becoming Canada's Cannabis Company.
VANCOUVER , Feb. 5, 2018 /PRNewswire/ - INVICTUS MD STRATEGIES CORP.'s ("Invictus" or the "Company") (TSXV: IMH; OTC: IVITF; FRA: 8IS1) is pleased to announce that it has received an ...
Invictus Receives $16.5 Million from Warrants and Option Exercises Since Dec 22, 2017 and Increases Funded Capacity in 2018 to 27,200 Kg
FRA: 8IS1) Acreage Pharms Ltd. ("Acreage Pharms") is pleased to announce the acquisition of cannabis oil extraction equipment and the hiring of key professionals to launch an extraction program to serve Canada's expanding need for high-quality cannabis oils. The C02 extraction technology, on track for production, will use Acreage Pharm's cannabis to extract and manufacture cannabis oils. Acreage Pharms will apply for an oil license from Health Canada as soon as it receives sales licenses expected.
Invictus's Acreage Pharms Launches Innovative, Ambitious Extraction Program for Cannabis Oils
FRA: 8IS1) is pleased to announce the sale of its first 120 kg of dried flower from AB Laboratories Inc. (AB Labs), the licensed production facility under the Access to Cannabis for Medical Purposes Regulations ("ACMPR"), near Hamilton to Canopy Growth Corporation (WEED.TO), putting Invictus MD's license holders on track for achieving 26,000 kg run-rate production capacity for 2018 with net capacity of 22,150 kilograms to Invictus MD. Additionally, the Company is pleased to announce that it has signed the definitive agreement to make its further strategic investment in AB Labs, from its current 33.3 percent ownership interest to 50 percent.
Invictus MD Jumpstarts Revenue Stream With Sale of First 120 kg of Flower to Canopy Growth Corporation; Signs Definitive Agreement to Increase Ownership of AB Laboratories in Ontario from 33.3% to 50%
VANCOUVER , Jan. 15, 2018 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company") (TSXV: IMH; OTC: IVITF; FRA: 8IS1) is pleased to announce that since the release ...